SCHEMBL1666550

SCHEMBL1666550

CCC(C)(C)C(=O)C(CCSC)C(=O)O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RNPEP Q9H4A4 1/20 0.46
FOLH1 Q04609 2/20 0.40
ALDH1A1 P00352 3/20 0.36
KDM4E B2RXH2 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
USP2 O75604 2/20 0.33
TSHR P16473 1/20 0.33
CTSS P25774 1/20 0.33
CTSK P43235 1/20 0.33
LMNA P02545 2/20 0.33
MAPK1 P28482 2/20 0.31
TP53 P04637 1/20 0.31
ALOX15 P16050 1/20 0.31
NPSR1 Q6W5P4 1/20 0.31
CA2 P00918 1/20 0.31
CHRM1 P11229 1/20 0.30
AKR1A1 P14550 1/20 0.30
CHRM3 P20309 1/20 0.30
HTR2A P28223 1/20 0.30
HTR2C P28335 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4290322 0.82 KIF11 (0.33) RNPEPFOLH1
SCHEMBL20877707 0.78 RNPEP (0.37) RNPEPFOLH1ALDH1A1KDM4EL3MBTL1
SCHEMBL4956698 0.77 RNPEP (0.62) RNPEPFOLH1ALDH1A1KDM4EL3MBTL1
SCHEMBL17433678 0.76 CA2 (0.37) MAPK1CA2CHRM1AKR1A1CHRM3
SCHEMBL474110 0.72 ENPEP (0.35) ALDH1A1KDM4EALOX15
SCHEMBL1664400 0.72 RIPK1 (0.31) MAPK1CA2CHRM1AKR1A1CHRM3
SCHEMBL3736721 0.72 RNPEP (0.47) RNPEPFOLH1ALDH1A1TSHRCTSS
SCHEMBL3736726 0.72 RNPEP (0.47) RNPEPFOLH1ALDH1A1TSHRCTSS
SCHEMBL9463332 0.71 RNPEP (0.56) RNPEPFOLH1ALDH1A1KDM4EL3MBTL1
SCHEMBL8460951 0.71 TSHR (0.32) TSHRMAPK1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11926857-B2 Variant LovD polypeptides and their uses CODEXIS, INC. (US) 2024-03-12 US disclosed
US-20210277432-A1 VARIANT LOVD POLYPEPTIDES AND THEIR USES INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT 2021-09-09 US disclosed
US-11046982-B2 Variant LovD polypeptides and their uses CODEXIS, INC. (US) 2021-06-29 US disclosed
US-20200157588-A1 VARIANT LOVD POLYPEPTIDES AND THEIR USES INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT 2020-05-21 US disclosed
US-10590445-B2 Variant LovD polypeptides and their uses CODEXIS, INC. (US) 2020-03-17 US disclosed
US-20180187225-A1 VARIANT LOVD POLYPEPTIDES AND THEIR USES INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT 2018-07-05 US disclosed
US-9932616-B2 Variant LovD polypeptides and their uses CODEXIS, INC. (US) 2018-04-03 US disclosed
US-20170081685-A1 VARIANT LOVD POLYPEPTIDES AND THEIR USES INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT 2017-03-23 US disclosed
US-9546388-B2 Variant LovD polypeptides and their uses CODEXIS, INC. (US) 2017-01-17 US disclosed
US-9181570-B2 Variant LovD polypeptides and their uses CODEXIS, INC. (US) 2015-11-10 US disclosed
CN-102574896-B variant LovD polypeptides and uses thereof CODEXIS INC 2015-04-08 CN disclosed
US-20150037851-A1 VARIANT LOVD POLYPEPTIDES AND THEIR USES INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT 2015-02-05 US disclosed
EP-2483292-B1 VARIANT LOVD POLYPEPTIDES AND THEIR USES CODEXIS INC (US) 2014-11-12 EP disclosed
US-8846362-B2 Variant LOVD polypeptides and their uses CODEXIS, INC. (US) 2014-09-30 US disclosed
US-20130130351-A1 VARIANT LOVD POLYPEPTIDES AND THEIR USES CODEXIS, INC. (US) 2013-05-23 US disclosed
US-8383382-B2 Variant LovD polypeptides and their uses CODEXIS, INC. (US) 2013-02-26 US disclosed
EP-2483292-A1 VARIANT LOVD POLYPEPTIDES AND THEIR USES Codexis, Inc. (US) 2012-08-08 EP disclosed
CN-102574896-A Variant LovD polypeptides and uses thereof CODEXIS INC 2012-07-11 CN disclosed
US-20110111468-A1 VARIANT LOVD POLYPEPTIDES AND THEIR USES CODEXIS, INC. (US) 2011-05-12 US disclosed
WO-2011041231-A1 VARIANT LOVD POLYPEPTIDES AND THEIR USES CODEXIS, INC. (US) 2011-04-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10590445-B2 Variant LovD polypeptides and their uses LCAT, HMGCR, FNTA RNPEP 395/4885FOLH1 440/4885ALDH1A1 3660/4885
US-11046982-B2 Variant LovD polypeptides and their uses LCAT, HMGCR, FNTA RNPEP 395/4885FOLH1 440/4885ALDH1A1 3660/4885
US-20210277432-A1 VARIANT LOVD POLYPEPTIDES AND THEIR USES LCAT, HMGCR, FNTA RNPEP 395/4885FOLH1 440/4885ALDH1A1 3660/4885
US-11926857-B2 Variant LovD polypeptides and their uses LCAT, HMGCR, FNTA RNPEP 395/4885FOLH1 440/4885ALDH1A1 3660/4885
US-20200157588-A1 VARIANT LOVD POLYPEPTIDES AND THEIR USES LCAT, HMGCR, FNTA RNPEP 395/4885FOLH1 440/4885ALDH1A1 3660/4885
US-20180187225-A1 VARIANT LOVD POLYPEPTIDES AND THEIR USES LCAT, HMGCR, FNTA RNPEP 395/4885FOLH1 440/4885ALDH1A1 3660/4885
US-20110111468-A1 VARIANT LOVD POLYPEPTIDES AND THEIR USES PCSK9, HMGCR, LCAT RNPEP 338/4885FOLH1 305/4885ALDH1A1 4006/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.